Accessing/VBG
Epstein-Barr/JJ
virus-specific/JJ
T-cell/NN
memory/NN
with/IN
peptide-loaded/JJ
dendritic/JJ
cells/NNS
./.

The/DT
conventional/JJ
means/NNS
of/IN
studying/VBG
Epstein-Barr/JJ
virus/NN
(/(
EBV/NN
)/)
-induced/JJ
cytotoxic/JJ
T-lymphocyte/NN
(/(
CTL/NN
)/)
memory/NN
,/,
by/IN
in/FW
vitro/FW
stimulation/NN
with/IN
the/DT
latently/RB
infected/JJ
autologous/JJ
lymphoblastoid/JJ
cell/NN
line/NN
(/(
LCL/NN
)/)
,/,
has/VBZ
important/JJ
limitations/NNS
./.
=====
First/RB
,/,
it/PRP
gives/VBZ
no/DT
information/NN
on/IN
memory/NN
to/TO
lytic/JJ
cycle/NN
antigens/NNS
;/:
second/RB
,/,
it/PRP
preferentially/RB
amplifies/VBZ
the/DT
dominant/JJ
components/NNS
of/IN
latent/JJ
antigen-specific/JJ
memory/NN
at/IN
the/DT
expense/NN
of/IN
key/JJ
subdominant/JJ
reactivities/NNS
./.
=====
Here/RB
we/PRP
describe/VBP
an/DT
alternative/JJ
approach/NN
,/,
based/VBN
on/IN
in/FW
vitro/FW
stimulation/NN
with/IN
epitope/NN
peptide-loaded/JJ
dendritic/JJ
cells/NNS
(/(
DCs/NNS
)/)
,/,
which/WDT
allows/VBZ
one/PRP
to/TO
probe/VB
the/DT
CTL/NN
repertoire/NN
for/IN
any/DT
individual/JJ
reactivity/NN
of/IN
choice/NN
;/:
this/DT
method/NN
proved/VBD
significantly/RB
more/RBR
efficient/JJ
than/IN
stimulation/NN
with/IN
peptide/NN
alone/RB
./.
=====
Using/VBG
this/DT
approach/NN
we/PRP
first/RB
show/VBP
that/IN
reactivities/NNS
to/TO
the/DT
immunodominant/JJ
and/CC
subdominant/JJ
lytic/JJ
cycle/NN
epitopes/NNS
identified/VBN
by/IN
T/NN
cells/NNS
during/IN
primary/JJ
EBV/NN
infection/NN
are/VBP
regularly/RB
detectable/JJ
in/IN
the/DT
CTL/NN
memory/NN
of/IN
virus/NN
carriers/NNS
;/:
this/DT
implies/VBZ
that/IN
in/IN
such/JJ
carriers/NNS
chronic/JJ
virus/NN
replication/NN
remains/VBZ
under/IN
direct/JJ
T-cell/NN
control/NN
./.
=====
We/PRP
further/RB
show/VBP
that/IN
subdominant/JJ
latent/JJ
cycle/NN
reactivities/NNS
to/TO
epitopes/NNS
in/IN
the/DT
latent/JJ
membrane/NN
protein/NN
LMP2/NN
,/,
though/IN
rarely/RB
undetectable/JJ
in/IN
LCL-stimulated/JJ
populations/NNS
,/,
can/MD
be/VB
reactivated/VBN
by/IN
DC/NN
stimulation/NN
and/CC
selectively/RB
expanded/VBN
as/IN
polyclonal/JJ
CTL/NN
lines/NNS
;/:
the/DT
adoptive/JJ
transfer/NN
of/IN
such/JJ
preparations/NNS
may/MD
be/VB
of/IN
value/NN
in/IN
targeting/VBG
certain/JJ
EBV-positive/JJ
malignancies/NNS
./.